1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH SBIR and STTR Funding Opportunities is a grant from National Institutes of Health (NIH) that funds small businesses developing innovative biomedical technologies. Through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, eligible U.S.-owned for-profit companies with fewer than 500 employees can receive up to ,000 for Phase I and up to . 8 million for Phase II awards.
Funds support early-stage research and development aimed at improving health outcomes and commercializing discoveries. Standard application due dates are September 5, January 5, and April 5. NIH also offers complementary resources such as Technical and Business Assistance (TABA) and the Commercialization Readiness Pilot to help companies transition research into viable health products.
Get alerted about grants like this
Save a search for “National Institutes of Health (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
U.S. Department of Health and Human Services National Institutes of Health Learn if your company is eligible for NIH SBIR or STTR funding, how to apply , and what to expect during each step of the application process. Multiple registrations are required to prepare your application and apply for funding.
Small Business Program Basics Understanding SBIR and STTR Foreign Disclosure and Risk Management SBIR and STTR Grants (NOFO s ) SBIR Contract Solicitations Commercialization Readiness Pilot (CRP) Small Business Transition Grant for New Entrepreneurs Navigate NIH's Research Areas Applicant Assistance Programs --> Transition Award (Coming Soon) Our team can help you maximize the benefits from NIH programs and resources which help you bring your innovations to life.
NIH's Technical and Business Assistance (TABA) Concept to Clinic Commercializing Innovation (C3i) The NIH is actively turning discovery into health by helping small businesses develop innovative technologies that improve health and save lives. See how .
Small Business Portfolio Overview Active Small Business Awards Research Evaluation and Commercialization Hubs (REACH) Search Technologies from Academic Centers and Hubs Our team can help you maximize the benefits from NIH programs and resources which help you bring your innovations to life. We value biomedical innovation and strive to empower scientists and entrepreneurs to bring their discoveries to patients.
HHS Small Business Program Managers Non-dilutive funding for early-stage research and development. [ Parent Announcements ] [ Specific Opportunities ] More information on HHS SBIR contracts is available on the NIH SBIR contracts webpage . NIH has committed $20 million to support academic product development and innovation.
Learn more about the five new Research Evaluation and Commercialization Hubs (REACH) in the funding opportunity announcement (RFA-OD-23-005) Standard Application Due Dates are September 5, January 5, and April 5. Due dates that fall on weekends or Federal holidays are moved to the next business day.
NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional) Some SBIR/STTR grant solicitations are focused on specific research areas.
Some specific NOFOs, identified as RFAs (Requests for Applications) or PASs (Program Announcements with Set-aside funds), have funding set-aside in the Institute/Center's budget for that targeted program. National Institutes of Health Product Development Support Looking for the NIH SBIR & STTR site? The new seed.
nih. gov has everything you’re looking for about the NIH small business research and development programs (SBIR & STTR) . In addition, you can learn about other types of product development and commercialization support for NIH award recipients .
Questions? Check out About the NIH SEED Office or email us at [email protected] .
Based on current listing details, eligibility includes: U. S. -owned, for-profit small businesses with fewer than 500 employees. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Typically up to $275,000 for Phase I; up to $1.8 million for Phase II Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Science Education Partnership Award (SEPA) is sponsored by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH). The Science Education Partnership Award (SEPA) Program funds grants for innovative educational programs that create partnerships among biomedical and clinical researchers and K-12 teachers and schools, museums and science centers, media experts, and other educational organizations. The program aims to improve STEM literacy through innovative P-12 and informal science education. Projects can be classroom-based or informal science education projects in venues such as science centers, museums, and libraries.
Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) is sponsored by National Institutes of Health (NIH). This K23 award supports individuals with a clinical doctoral degree who propose to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development in patient-oriented research.
Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH), National Institutes of Health (NIH). This funding opportunity is a companion to the R21 mechanism and also aims to stimulate research to understand the link between social disconnection and suicidal thoughts and behaviors in late life. It focuses on identifying mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. This R01 mechanism is appropriate for applications with preliminary data.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.